Clozapine Use Pattern in the Province of Seville

October 6, 2021 updated by: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
CLOZAPINE USE PATTERN IN THE PROVINCE OF SEVILLE

Study Overview

Status

Completed

Conditions

Detailed Description

Subjects with a diagnosis of schizophrenia (F20 of ICD-10) under treatment with clozapine in the province of Seville. The use of clozapine, variability between centers and treatment modification will be identified.

Study Type

Observational

Enrollment (Actual)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Sevilla, Spain, 41013
        • Hospital Universitario Virgen del Rocio

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.

Description

Inclusion Criteria:

Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.

Exclusion Criteria:

  • Parkinson's disease
  • Dementia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Patients who have been prescribed clozapine during 2018
Patients who have been prescribed (initially or regularly) clozapine during 2018, based on the casuistry provided by the Pharmacy service of the different hospitals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identify the pattern of clozapine use in the province of Seville
Time Frame: year 2018
Identify the pattern of clozapine use in the province of Seville
year 2018

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Analyze the variability between centers or professionals
Time Frame: year 2018
Analyze the variability between centers or professionals
year 2018
Analyze the changes in the course of the disease since the prescription of clozapine
Time Frame: year 2018
Analyze the changes in the course of the disease since the prescription of clozapine
year 2018

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 8, 2020

Primary Completion (Actual)

September 8, 2021

Study Completion (Actual)

September 8, 2021

Study Registration Dates

First Submitted

October 6, 2021

First Submitted That Met QC Criteria

October 6, 2021

First Posted (Actual)

October 19, 2021

Study Record Updates

Last Update Posted (Actual)

October 19, 2021

Last Update Submitted That Met QC Criteria

October 6, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CLOZASEV

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia and Related Disorders

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe